Deverra Therapeutics Granted FDA Fast Track Designation for DVX101 (Dilanubicel) for the Treatment of Acute Myeloid Leukemia
Accesswire
*Designation Validates Preliminary Data and Supports Accelerated Drug Development*
*SEATTLE, WA / ACCESSWIRE / April 24,..
